Penn Dental Medicine's Innovative Study on Plant-Encapsulated GLP-1 Drug Delivery System
In the rapidly evolving world of pharmaceuticals, few therapeutic agents have garnered as much attention as glucagon-like peptide-1 (GLP-1) receptor agonists. These medications, originally approved for treating type 2 diabetes, have significantly impacted obesity management as well. Despite their proven effectiveness in stimulating insulin secretion and reducing appetite, issues such as high manufacturing costs and side effects hamper their broader adoption, particularly in lower-income regions.
A pioneering study from Penn Dental Medicine, led by Professor Henry Daniell, aims to address these challenges by investigating a new method of delivering GLP-1 drugs such as exenatide and lixisenatide through innovative plant encapsulation techniques. Published in the prestigious Plant Biotechnology Journal, the findings suggest that lettuce chloroplasts can be genetically engineered to produce functional GLP-1 peptides. This breakthrough could potentially decrease costs and enhance the tolerability of oral medications for diabetes and obesity.
Professor Daniell underscores the urgency of this research, noting that patient preference tends toward oral medications over weekly injections. "People don't want injections, even just one a week; they want pills," he emphasizes. However, the challenge lies in the fact that delivering peptides orally is tricky due to their degradation in the stomach and poor absorption in the intestines. Traditional oral formulations, such as the recently approved semaglutide, require strict adherence to fasting protocols, and common side effects like nausea can deter patients.
In response to these hurdles, Daniell's team has utilized genetic engineering to enable lettuce chloroplasts to express these crucial peptides. By doing so, they protect the GLP-1 peptides from digestive enzymes and allow for better absorption in the gastrointestinal tract. Daniell states, "We eat plant cells all the time. The natural composition of the lettuce provides an ideal medium for delivering these peptides without the risk of degradation during digestion."
The research notably shifts the approach to producing GLP-1 receptor agonists, as genetic integration into plant cells circumvents complicated steps involved in traditional peptide synthesis. Daniell explains, "The chloroplasts do this naturally. Plant cells modify these peptides effectively, which is beneficial since the modifications help enhance their functionality without the need for additional chemical alterations inherent in synthetic GLP-1 drugs. This development lowers the risk of adverse effects, as the natural forms of these peptides are less likely to induce gastrointestinal disturbances.
Another exciting aspect of this study is its promise to lower the overall production costs associated with GLP-1 receptor agonists. With the potential of deriving functional GLP-1 peptides directly from lettuce, Daniell optimistically remarks, "How much can you charge for a leaf of lettuce?" The simplicity and affordability of this method could revolutionize access to these essential medications in areas where they are currently out of reach.
Looking ahead, Daniell and his team are strategizing on scaling this production method to prepare larger batches of their plant-encapsulated GLP-1 receptor agonists, leveraging their prior experience in oral insulin production at Penn. "We are well-equipped to embark on early-stage clinical trials, paving the way for groundbreaking advancements in the dissemination of GLP-1 therapies," Daniell concludes.
This critical work received funding from the NIH grant R01 HL 107904, emphasizing its scientific significance and potential impact on future diabetes and obesity treatments.
A pioneering study from Penn Dental Medicine, led by Professor Henry Daniell, aims to address these challenges by investigating a new method of delivering GLP-1 drugs such as exenatide and lixisenatide through innovative plant encapsulation techniques. Published in the prestigious Plant Biotechnology Journal, the findings suggest that lettuce chloroplasts can be genetically engineered to produce functional GLP-1 peptides. This breakthrough could potentially decrease costs and enhance the tolerability of oral medications for diabetes and obesity.
Professor Daniell underscores the urgency of this research, noting that patient preference tends toward oral medications over weekly injections. "People don't want injections, even just one a week; they want pills," he emphasizes. However, the challenge lies in the fact that delivering peptides orally is tricky due to their degradation in the stomach and poor absorption in the intestines. Traditional oral formulations, such as the recently approved semaglutide, require strict adherence to fasting protocols, and common side effects like nausea can deter patients.
In response to these hurdles, Daniell's team has utilized genetic engineering to enable lettuce chloroplasts to express these crucial peptides. By doing so, they protect the GLP-1 peptides from digestive enzymes and allow for better absorption in the gastrointestinal tract. Daniell states, "We eat plant cells all the time. The natural composition of the lettuce provides an ideal medium for delivering these peptides without the risk of degradation during digestion."
The research notably shifts the approach to producing GLP-1 receptor agonists, as genetic integration into plant cells circumvents complicated steps involved in traditional peptide synthesis. Daniell explains, "The chloroplasts do this naturally. Plant cells modify these peptides effectively, which is beneficial since the modifications help enhance their functionality without the need for additional chemical alterations inherent in synthetic GLP-1 drugs. This development lowers the risk of adverse effects, as the natural forms of these peptides are less likely to induce gastrointestinal disturbances.
Another exciting aspect of this study is its promise to lower the overall production costs associated with GLP-1 receptor agonists. With the potential of deriving functional GLP-1 peptides directly from lettuce, Daniell optimistically remarks, "How much can you charge for a leaf of lettuce?" The simplicity and affordability of this method could revolutionize access to these essential medications in areas where they are currently out of reach.
Looking ahead, Daniell and his team are strategizing on scaling this production method to prepare larger batches of their plant-encapsulated GLP-1 receptor agonists, leveraging their prior experience in oral insulin production at Penn. "We are well-equipped to embark on early-stage clinical trials, paving the way for groundbreaking advancements in the dissemination of GLP-1 therapies," Daniell concludes.
This critical work received funding from the NIH grant R01 HL 107904, emphasizing its scientific significance and potential impact on future diabetes and obesity treatments.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.